Neuroinflammation, the inflammation of nervous tissue, stands as a critical pathological driver behind both acute brain insults (e.g., stroke, trauma, haemorrhage) and chronic neurodegenerative conditions including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. This process is initiated by cues like infection, toxic metabolites, or autoimmunity, triggering the activation of microglia—the resident innate immune cells of the central nervous system (CNS). When hyperactivated, microglia release excessive proinflammatory mediators, compromising the blood-brain barrier (BBB) and impairing neuronal survival. Among these mediators, nitric oxide (NO) plays a pivotal role in propagating inflammatory damage, making its inhibition a key target for anti-neuroinflammatory intervention.
Against this backdrop, Neuroinflammatory-IN-1 (also referred to as Compound 5 in scientific literature) emerges as a specialized bioactive agent. Classified under phenylpropanoids and coumarins—structural families with well-documented biological activities—it is originally derived from plants of the Umbelliferae family. With the CAS number 83988-97-0, a molecular formula of C₂₄H₃₀O₄, and a molecular weight of 382.49, this compound is engineered to target neuroinflammatory pathways at a molecular level. Its core functionality lies in inhibiting NO production, with an IC₅₀ value of 65.4 μM, positioning it as a valuable tool for dissecting NO-mediated inflammatory processes in the CNS.
Neuroinflammatory-IN-1